Cellular models of aggregation-dependent template-directed proteolysis to characterize Tau aggregation inhibitors for treatment of Alzheimer disease

Journal of Biological Chemistry

Volumn 290, Issue 17, 2015, Pages 10862-10875

  Harrington, Charles R ^a,b   Storey, John M D ^a,b   Clunas, Scott ^a   Harrington, Kathleen A ^a   Horsley, David ^a   Ishaq, Ahtsham ^a   Kemp, Steven J ^a   Larch, Christopher P ^a   Marshall, Colin ^a   Nicoll, Sarah L ^a   Rickard, Janet E ^a   Simpson, Michael ^a   Sinclair, James P ^a   Storey, Lynda J ^a   Wischik, Claude M ^a,b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b TAURX THERAPEUTICS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORINE COMPOUNDS; MOBILE SECURITY; NEURODEGENERATIVE DISEASES;

AGGREGATION INHIBITORS; ALZHEIMER DISEASE; BINDING DOMAIN; BRAIN TISSUE; CELLULAR MODEL; PAIRED HELICAL FILAMENTS; TAU PROTEINS; TRANSGENIC MICE;

BRAIN;

LEUCOMETHYLTHIONINIUM SALT; PROTEIN INHIBITOR; TAU PROTEIN; UNCLASSIFIED DRUG; LEUCOMETHYLENE BLUE; MAPT PROTEIN, HUMAN; METHYLENE BLUE; PROTEIN AGGREGATE; RECOMBINANT PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CELL CYCLE ARREST; CONTROLLED STUDY; CRYSTALLIZATION; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; MOUSE; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; RAMAN SPECTROMETRY; SITE DIRECTED MUTAGENESIS; ANALOGS AND DERIVATIVES; ANIMAL; BIOLOGICAL MODEL; BRAIN; CELL LINE; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; PROTEIN AGGREGATION, PATHOLOGICAL; SYNTHESIS; TRANSGENIC MOUSE;

MUS MUSCULUS;

ALZHEIMER DISEASE; ANIMALS; BRAIN; CELL LINE; HUMANS; METHYLENE BLUE; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; PROTEIN AGGREGATES; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEOLYSIS; RECOMBINANT PROTEINS; TAU PROTEINS;

EID: 84928401341     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.616029     Document Type: Article

References (58)

1. Alzheimer, A. (1907) Über eine eigenartige Erkrankung der Hirnrinde. Allg. Z. Psych. Psych.-gerich. Med. 64, 146-148
2. Wischik, C. M., Novak, M., Thøgersen, H. C., Edwards, P. C., Runswick, M. J., Jakes, R., Walker, J. E., Milstein, C., Roth, M., and Klug, A. (1988) Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 85, 4506-4510
3. Bancher, C., Braak, H., Fischer, P., and Jellinger, K. (1993) Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease. Neurosci. Lett. 162, 179-182
4. Bancher, C., Jellinger, K., Lassmann, H., Fischer, P., and Leblhuber, F. (1996) Correlations between mental state and quantitative neuropathology in the Vienna Longitudinal Study on Dementia. Eur. Arch. Psychiatry Clin. Neurosci. 246, 137-146
5. Duyckaerts, C., Bennecib, M., Grignon, Y., Uchihara, T., He, Y., Piette, F., and Hauw, J.-J. (1997) Modeling the relation between neurofibrillary tangles and intellectual status. Neurobiol. Aging 18, 267-273
6. Giannakopoulos, P., Hof, P. R., Michel, J.-P., Guimon, J., and Bouras, C. (1997) Cerebral cortex pathology in aging and Alzheimer's disease: a quantitative survey of large hospital-based geriatric and psychiatric cohorts. Brain Res. Rev. 25, 217-245
7. Grober, E., Dickson, D., Sliwinski, M. J., Buschke, H., Katz, M., Crystal, H., and Lipton, R. B. (1999) Memory and mental status correlates of modified Braak staging. Neurobiol. Aging 20, 573-579
8. Wilcock, G. K., and Esiri, M. M. (1982) Plaques, tangles and dementia: a quantitative study. J. Neurol. Sci. 56, 343-356
9. Wischik, C. M., Edwards, P. C., Lai, R. Y. K., Roth, M., and Harrington, C. R. (1996) Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc. Natl. Acad. Sci. U.S.A. 93, 11213-11218
10. Wischik, C. M., Staff, R. T., Wischik, D. J., Bentham, P., Murray, A. D., Storey, J. M. D., Kook, K. A., and Harrington, C. R. (2015) Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease. J. Alzheimers Dis. 44, 705-720
11. Baddeley, T. C., McCaffrey, J., Storey, J. M. D., Cheung, J. K. S., Melis, V., Horsley, D., Harrington, C. R., and Wischik, C. M. (2015) Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease. J. Pharmacol. Exp. Ther. 352, 110-118
12. Melis, V., Magbagbeolu, M., Rickard, J. E., Horsley, D., Davidson, K., Harrington, K. A., Goatman, K., Goatman, E. A., Close, S. P., Zabke, C., Stamer, K., Dietze, S., Schwab, K., Storey, J. M. D., Harrington, C. R., Wischik, C. M., Theuring, F., and Riedel, G. (2015) Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models. Behav. Pharmacol. 10.1097/FBP.0000000000000133
13. Rager, T., Geoffroy, A., Hilfiker, R., and Storey, J. M. D. (2012) The crystalline state of methylene blue: a zoo of hydrates. Phys. Chem. Chem. Phys. 14, 8074-8082
14. Harrington, C. R., Mukaetova-Ladinska, E. B., Hills, R., Edwards, P. C., Montejo de Garcini, E., Novak, M., and Wischik, C. M. (1991) Measurement of distinct immunochemical presentations of tau protein in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 88, 5842-5846
15. Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., and Crowther, R. A. (1989) Multiple isoforms of human microtubule-associated protein tau: sequences and localisation in neurofibrillary tangles of Alzheimer's disease. Neuron 3, 519-526
16. Goedert, M., and Jakes, R. (1990) Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerisation. EMBO J. 9, 4225-4230
17. Partridge, K. A., Johannessen, A., Tauler, A., Pryme, I. F., and Hesketh, J. E. (1999) Competition between the signal sequence and a 3′ UTR localisation signal during redirection of β-globin mRNA to the endoplasmic reticulum: implications for biotechnology. Cytotechnology 30, 37-47
18. Gorman, C. M., Howard, B. H., and Reeves, R. (1983) Expression of recombinant plasmids in mammalian cells is enhanced by sodium butyrate. Nucleic Acids Res. 11, 7631-7648
19. Kruh, J. (1982) Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol. Cell Biochem. 42, 65-82
20. Novak, M., Jakes, R., Edwards, P. C., Milstein, C., and Wischik, C. M. (1991) Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of mAbs 423 and 7.51. Proc. Natl. Acad. Sci. U.S.A. 88, 5837-5841
21. Kilmartin, J. V., Wright, B., and Milstein, C. (1982) Rat monoclonal anti-tubulin antibodies derived by using a new nonsecreting rat cell line. J. Cell Biol. 93, 576-582
22. Marr, H. E., 3rd, Stewart, J. M., and Chiu, M. F. (1973) Crystal structure of methylene blue pentahydrate. Acta Crystallogr. B 29, 847-853
23. Resch, J. F., Lehr, G. S., and Wischik, C. M. (1991) Design and synthesis of a potential affinity/cleaving reagent for β-pleated sheet protein structures. Bioorg. Med. Chem. Lett. 1, 519-522
24. Mena, R., Edwards, P., Pérez-Olvera, O., and Wischik, C. M. (1995) Monitoring pathological assembly of tau and β-amyloid proteins in Alzheimer's disease. Acta Neuropathol. 89, 50-56
25. Rankin, C. A., and Gamblin, T. C. (2008) Assessing the toxicity of tau aggregation. J. Alzheimers Dis. 14, 411-416
26. Baum, L., Seger, R., Woodgett, J. R., Kawabata, S., Maruyama, K., Koyama, M., Silver, J., and Saitoh, T. (1995) Overexpressed tau in cultured cells is phosphorylated without formation of PHF: implication of phosphoprotein phosphatase involvement. Mol. Brain Res. 34, 1-17
27. Lee, G., and Rook, S. L. (1992) Expression of tau protein in non-neuronal cells: microtubule binding and stabilization. J. Cell Sci. 102, 227-237
28. Fasulo, L., Ovecka, M., Kabát, J., Bradbury, A., Novák, M., and Cattaneo, A. (1996) Overexpression of Alzheimer's PHF core tau fragments: implications for the tau truncation hypothesis. Alzheimers Res. 2, 195-200
29. Bacallao, R., Sohrab, S., and Phillips, C. (2006) in Handbook of Biological Confocal Microscopy (Pawley, J. B., ed) pp. 368-380, 3rd Ed., Plenum Press, New York
30. Rogalski, A. A., and Singer, S. J. (1984) Associations of elements of the Golgi apparatus with microtubules. J. Cell Biol. 99, 1092-1100
31. Wischik, C. M., Lai, R. Y. K., and Harrington, C. R. (1997) in Brain Microtubule-associated Proteins: Modifications in Disease (Avila, J., Brandt, R., and Kosik, K. S., eds) pp. 185-241, Harwood Academic Publishers, Amsterdam
32. Wischik, C. M., Harrington, C. R., and Storey, J. M. D. (2014) Tau-aggregation inhibitor therapy for Alzheimer's disease. Biochem. Pharmacol. 88, 529-539
33. Chidley, J. S., Nylund, G. J., and Dolinsky, H. (August 26, 1969) Security seal. United States Patent 3463532
34. Chirita, C., Necula, M., and Kuret, J. (2004) Ligand-dependent inhibition and reversal of tau filament formation. Biochemistry 43, 2879-2887
35. Crowe, A., Ballatore, C., Hyde, E., Trojanowski, J. Q., and Lee, V. M. Y. (2007) High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Biochem. Biophys. Res. Commun. 358, 1-6
36. Hall, G. F., Lee, S., and Yao, J. (2002) Neurofibrillary degeneration can be arrested in an in vivo cellular model of human tauopathy by application of a compound which inhibits tau filament formation in vitro. J. Mol. Neurosci. 19, 253-260
37. Pickhardt, M., Gazova, Z., von Bergen, M., Khlistunova, I., Wang, Y., Hascher, A., Mandelkow, E.-M., Biernat, J., and Mandelkow, E. (2005) Anthraquinones inhibit tau aggregation and dissolve Alzheimer paired helical filaments in vitro and in cells. J. Biol. Chem. 280, 3628-3635
38. Taniguchi, S., Suzuki, N., Masuda, M., Hisanaga, S., Iwatsubo, T., Goedert, M., and Hasegawa, M. (2005) Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 280, 7614-7623
39. Wischik, C. M., Horsley, D., Rickard, J. E., and Harrington, C. R. (February 26, 2008) Materials and methods relating to protein aggregation in neurodegenerative disease. United States Patent 7335505
40. Kanai, Y., Takemura, R., Oshima, T., Mori, H., Ihara, Y., Yanagisawa, M., Masaki, T., and Hirokawa, N. (1989) Expression of multiple tau isoforms and microtubule bundle formation in fibroblasts transfected with a single tau cDNA. J. Cell Biol. 109, 1173-1184
41. Mena, R., Edwards, P. C., Harrington, C. R., Mukaetova-Ladinska, E. B., and Wischik, C. M. (1996) Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease. Acta Neuropathol. 91, 633-641
42. Perreault, S., Bousquet, O., Lauzon, M., Paiement, J., and Leclerc, N. (2009) Increased association between rough endoplasmic reticulum membranes and mitochondria in transgenic mice that express P301L tau. J. Neuropathol. Exp. Neurol. 68, 503-514
43. Lai, R. Y. K., Gertz, H.-N., Wischik, D. J., Xuereb, J. H., Mukaetova-Ladinska, E. B., Harrington, C. R., Edwards, P. C., Mena, R., Paykel, E. S., Brayne, C., Huppert, F. A., Roth, M., and Wischik, C. M. (1995) Examination of phosphorylated tau protein as a PHF-precursor at early stage Alzheimer's disease. Neurobiol. Aging 16, 433-445
44. Schneider, A., Biernat, J., von Bergen, M., Mandelkow, E., and Mandelkow, E.-M. (1999) Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 38, 3549-3558
45. Crowther, R. A., Olesen, O. F., Jakes, R., and Goedert, M. (1992) The microtubule binding repeats of tau protein assemble into filaments like those found in Alzheimer's disease. FEBS Lett. 309, 199-202
46. Akoury, E., Pickhardt, M., Gajda, M., Biernat, J., Mandelkow, E., and Zweckstetter, M. (2013) Mechanistic basis of phenothiazine-driven inhibition of tau aggregation. Angew. Chem. Int. Ed. Engl. 52, 3511-3515
47. Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., Staufenbiel, M., Jucker, M., Goedert, M., and Tolnay, M. (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nature Cell Biol. 11, 909-913
48. Frost, B., Jacks, R. L., and Diamond, M. I. (2009) Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 284, 12845-12852
49. Hrnkova, M., Zilka, N., Minichova, Z., Koson, P., and Novak, M. (2007) Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic rats. Brain Res. 1130, 206-213
50. Zilka, N., Filipcik, P., Koson, P., Fialova, L., Skrabana, R., Zilkova, M., Rolkova, G., Kontsekova, E., and Novak, M. (2006) Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett. 580, 3582-3588
51. Clavaguera, F., Lavenir, I., Falcon, B., Frank, S., Goedert, M., and Tolnay, M. (2013) "Prion-Like" templated misfolding in tauopathies. Brain Pathol. 23, 342-349
52. Melis, V., Zabke, C., Stamer, K., Magbagbeolu, M., Schwab, K., Marschall, P., Veh, R. W., Bachmann, S., Deiana, S., Moreau, P. H., Davidson, K., Harrington, K. A., Rickard, J. E., Horsley, D., Garman, R., Mazurkiewicz, M., Niewiadomska, G., Wischik, C. M., Harrington, C. R., Riedel, G., and Theuring, F. (2015) Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer's disease and frontotemporal lobar degeneration. Cell Mol. Life Sci. 10.1007/s00018-00014-01804-z
53. Honson, N. S., Jensen, J. R., Darby, M. V., and Kuret, J. (2007) Potent inhibition of tau fibrillization with a multivalent ligand. Biochem. Biophys. Res. Commun. 363, 229-234
54. Pickhardt, M., Larbig, G., Khlistunova, I., Coksezen, A., Meyer, B., Mandelkow, E. M., Schmidt, B., and Mandelkow, E. (2007) Phenylthiazolylhydrazide and its derivatives are potent inhibitors of τ aggregation and toxicity in vitro and in cells. Biochemistry 46, 10016-10023
55. Li, W., Sperry, J. B., Crowe, A., Trojanowski, J., Q., Smith, A. B., 3rd, and Lee, V. M. Y. (2009) Inhibition of tau fibrillization by oleocanthal via reaction with the amino groups of tau. J. Neurochem. 110, 1339-1351
56. Bulic, B., Pickhardt, M., Schmidt, B., Mandelkow, E. M., Waldmann, H., and Mandelkow, E. (2009) Development of tau aggregation inhibitors for Alzheimer's disease. Angew. Chem. Int. Ed. Engl. 48, 1740-1752
57. Bulic, B., Pickhardt, M., Khlistunova, I., Biernat, J., Mandelkow, E.-M., Mandelkow, E., and Waldmann, H. (2007) Rhodanine-based tau aggregation inhibitors in cell models of tauopathy. Angew. Chem. Int. Ed. Engl. 46, 9215-9219
58. Fatouros, C., Pir, G. J., Biernat, J., Koushika, S. P., Mandelkow, E., Mandelkow, E. M., Schmidt, E., and Baumeister, R. (2012) Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity. Hum. Mol. Genet. 21, 3587-3603